crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Trading 06-30 15:29:25 EDT

222.95

+2.64

+1.20%

High223.96	Low219.84	Vol153.26K
Open221.75	D1 Closing220.31	Amplitude1.87%
Mkt Cap12.84B	Tradable Cap10.87B	Total Shares57.60M
T/O34.08M	T/O Rate0.31%	Tradable Shares48.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":222.95,"timestamp":1782847760334,"preClose":220.31,"halted":0,"volume":153262,"delay":0,"changeRate":0.01198311470201074,"floatShares":48764858,"shares":57596887,"eps":5.56358,"marketStatus":"Trading","change":2.64,"latestTime":"06-30 15:29:25 EDT","open":221.75,"high":223.96,"low":219.8401,"amount":34082322.33114,"amplitude":0.0187,"askPrice":223.07,"askSize":8,"bidPrice":222.79,"bidSize":4,"shortable":3,"etf":0,"ttmEps":5.56358,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782849600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":220.31,"dividendRate":0.004376,"preHourTrading":{"tag":"盘前","latestPrice":220.2,"preClose":220.31,"latestTime":"07:00 EDT","volume":25,"amount":5505,"timestamp":1782817209618,"change":-0.11,"changeRate":-0.000499,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":220.31,"preClose":220.31,"latestTime":"16:10 EDT","volume":6632,"amount":1461095.92,"timestamp":1782763804828,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.31457,"impliedVol":0.3882,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/CR/wiki","defaultTab":"wiki","newsList":[{"id":"2647555004","title":"Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555004","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647555004?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:30","pubTimestamp":1782822600,"startTime":"0","endTime":"0","summary":"Moleculin Biotech, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/30/3319693/0/en/Moleculin-Reports-Positive-Phase-2-3-MIRACLE-Interim-Results-With-Annamycin-Complete-Remission-Rates-3-fold-Greater-than-Control.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITT","CR","BK4161","LU0053671581.USD","LU0054578231.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647112371","title":"Crane Updates Financial Calendar with Second-quarter 2026 Earnings Release, Teleconference Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2647112371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647112371?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736217,"startTime":"0","endTime":"0","summary":"Crane updates financial calendar with second-quarter 2026 earnings release, teleconference scheduleCrane set its second-quarter 2026 earnings release for July 28, 2026, posted to http://www.craneco.co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL8MgNX8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647137190","title":"Crane Company Announces Date for Second Quarter 2026 Earnings Release and Teleconference","url":"https://stock-news.laohu8.com/highlight/detail?id=2647137190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647137190?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:30","pubTimestamp":1782736200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA31CGV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643246367","title":"Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2643246367","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643246367?lang=en_us&edition=fundamental","pubTime":"2026-06-14 15:15","pubTimestamp":1781421300,"startTime":"0","endTime":"0","summary":"Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311435/0/en/Legend-Biotech-Establishes-Clinical-Proof-of-Concept-for-LB2501-a-Potential-First-in-Class-In-Vivo-CD19-CD20-Dual-Targeting-CAR-T-in-Relapsed-Refractory-B-Cell-Non-Hodgkin-Lymphoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","IE0031619046.USD","BK4187","BK4588","IE00B66KJ199.SGD","BK4022","BK4505","LEGN","BK4006","CRS","CAR","BK4230","BK4139","ORR","IRR","BK4161","IE00B7SZL793.SGD","BK4581","CR","IE00B19Z4B17.USD","LU2065731478.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217815","title":"Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217815","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643217815?lang=en_us&edition=fundamental","pubTime":"2026-06-14 00:45","pubTimestamp":1781369100,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly di","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/13/3311409/0/en/Genmab-Announces-Epcoritamab-Monotherapy-and-Epcoritamab-Based-Combination-Regimens-Demonstrate-High-Response-Rates-in-Elderly-Patients-with-Newly-Diagnosed-Diffuse-Large-B-Cell-Ly.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","BK4187","IE0031619046.USD","IE00B7SZL793.SGD","LU2065731478.USD","BK4006","CR","LU0963586101.USD","CRS","PFS","BK4211","BK4161","ORR","IE00B66KJ199.SGD","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184285696","title":"Honda Recalls Over One Million Vehicles in the U.S., Primarily Affecting CR-V and Accord Hybrid Models","url":"https://stock-news.laohu8.com/highlight/detail?id=1184285696","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184285696?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:30","pubTimestamp":1781191841,"startTime":"0","endTime":"0","summary":"Honda's American division announced this week that it will recall approximately 1.05 million vehicles in the United States due to a safety hazard associated with the tire repair kits included with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238199","title":"Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating  Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642238199?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:45","pubTimestamp":1781189100,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lena","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310630/0/en/Genmab-Presents-EPCORE-FL-1-Subgroup-Data-Demonstrating-Consistent-Efficacy-and-Safety-Results-for-Epcoritamab-in-Combination-with-Rituximab-and-Lenalidomide-R2-Across-Relapsed-or-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4211","CR","BK4161","PFS","BK4195","BK4203","HR","BK4225"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289420","title":"Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289420","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289420?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:03","pubTimestamp":1781175780,"startTime":"0","endTime":"0","summary":"–Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – –Ph 1 trial of revumenib with int","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310342/0/en/Syndax-Showcases-Revuforj-revumenib-Clinical-Activity-in-Multiple-Acute-Leukemia-Subtypes-and-Settings-at-EHA-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4500","ECG","LU1571399168.USD","LU0985320562.USD","LU1699723380.USD","BK4161","SAVE","ALL","ORR","CR","LU2355687059.USD","BK4107","BK4129","HSCT","BK4585","BK4533","LU1559883803.SGD","LU0566484027.USD","BK4588","BK4008"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289288","title":"C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289288","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289288?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"At the 100 g Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-for-Multiple-Myelo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","BK4196","LU1261432733.SGD","PR","LU0868494617.USD","EPV","BK4139","BK4161","IE00B19Z3581.USD","CR","ORR","IE0002270589.USD","CCCC","CI","BK4213","BK4585","LU0058720904.USD","BK4588","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642401957","title":"Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2642401957","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642401957?lang=en_us&edition=fundamental","pubTime":"2026-06-11 14:40","pubTimestamp":1781160000,"startTime":"0","endTime":"0","summary":"NEW YORK, June  11, 2026  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310207/0/en/Cellectis-Presents-Final-Phase-1-Results-of-Lasme-cel-and-Preliminary-Results-on-Eti-cel-at-EHA-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","CLLS","BK4022","LU2065731478.USD","BK4187","ADC","CR","CRS","BK4230","BK4161","IE0031619046.USD","IE00B66KJ199.SGD","ORR","IE00B7SZL793.SGD","LU0963586101.USD","BK4080","HSCT","BK4139","IE00B19Z4B17.USD","BK4006","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642526451","title":"Crane NXT unit Antares Vision debuts laser spectroscopy leak detection tech at ProPak Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2642526451","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642526451?lang=en_us&edition=fundamental","pubTime":"2026-06-09 12:58","pubTimestamp":1780981134,"startTime":"0","endTime":"0","summary":"Crane NXT-controlled Antares Vision Group will attend ProPak Asia 2026 in Bangkok on June 10-13.Event will feature the Thailand debut of laser spectroscopy-based in-line leak detection for sealed containers, targeting beverages, aerosols, liquid food.Antares will also present an in-line leak detection system for MAP packaging, aimed at 100% inspection without tracer gases.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL4d7J9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4157","LU0757428866.USD","LU1815336091.USD","BK4161","CXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640978848","title":"ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978848","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640978848?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:47","pubTimestamp":1780454820,"startTime":"0","endTime":"0","summary":"BEIJING, June  02, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305756/0/en/ASCO-2026-Updated-Data-from-an-Oral-Presentation-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-in-MDS-and-AML-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTD","BK4121","IE00BFXG0V08.USD","LU2413666699.HKD","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","BK4161","LU1093756325.SGD","BK4548","BK4533","CR","BK4567","ORR","LU0347712357.USD","LU1721428933.USD","LU2413666426.HKD","LU2211817866.USD","BK4585","LU1093756168.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640111966","title":"Crane Is Maintained at Buy by DA Davidson","url":"https://stock-news.laohu8.com/highlight/detail?id=2640111966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640111966?lang=en_us&edition=fundamental","pubTime":"2026-06-02 01:46","pubTimestamp":1780335960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 13:46 ET (17:46 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989428","title":"Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989428","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989428?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303964/0/en/Ascentage-Pharma-Presents-Data-on-Olverembatinib-in-CML-LBP-and-Ph-BCP-ALL-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","EMA","LU0985320562.USD","LU2355687059.USD","LU1699723380.USD","BK4139","BK4107","ALL","BK4161","BK4585","BK4081","AAPG","BK4588","LU1571399168.USD","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640894409","title":"Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640894409","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640894409?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303965/0/en/Ascentage-Pharma-Presents-Its-First-Dataset-on-MDM2-p53-Inhibitor-Alrizomadlin-APG-115-in-Pediatric-Solid-Tumors-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NB","BK4017","APG","BK4161","LU2125909916.SGD","BK4139","BK4168","BK4129","CR","EWS","CDE","LU1223082196.USD","LU1223083913.SGD","LU1923622291.USD","LU1223082519.USD","LU2125909759.SGD","AAPG","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639279156","title":"Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits","url":"https://stock-news.laohu8.com/highlight/detail?id=2639279156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639279156?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:21","pubTimestamp":1780057260,"startTime":"0","endTime":"0","summary":"Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May  29, 2026  (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (N","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303566/0/en/Moleculin-Presents-ASCO-2026-Data-Demonstrating-No-Detectable-Cardiotoxicity-with-Annamycin-Despite-Exposure-Levels-Far-Exceeding-Conventional-Anthracycline-Limits.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667234","title":"PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667234","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667234?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:00","pubTimestamp":1779966000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor -targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association .\"When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical need, with very limited treatment options remaining,\" said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. \"These durable CRs clinically validate BAFF-R as a novel target, while the favorable safety profile observed to date may support future use in outpatient community oncology settings and further exploration in refractory autoimmune diseases.\". PeproMene Bio, Inc. is a clinical-stage biotech company in Irvine, California developing novel therapies to treat cancers and immune disorders. For more information, c","market":"hk","thumbnail":"https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pepromene-bio-announces-oral-presentation-at-eha-2026-highlighting-favorable-safety-and-durable-responses-with-pmb-ct01-baff-r-car-t-cell-therapy-in-b-cell-lymphomas-including-after-prior-cd19-car-t-cell-failure-302783633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","CR","LU0963586101.USD","IE0031619046.USD","MRD.AU","BK7095","BK4022","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU2065731478.USD","BK4161","BK4187","BK4230","IE00B7SZL793.SGD","CRS.AU","CRS","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637116373","title":"2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2637116373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637116373?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:00","pubTimestamp":1779451200,"startTime":"0","endTime":"0","summary":"BEIJING, May  22, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300080/0/en/2026-ASCO-Pivotal-Data-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4161","ORR","BK4211","IE00B64QTZ34.USD","PB","PFS","IE00BLDYK493.USD","CR","TLS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365900","title":"Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365900","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637365900?lang=en_us&edition=fundamental","pubTime":"2026-05-22 08:00","pubTimestamp":1779408000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  21, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3299861/0/en/Ascentage-Pharma-Releases-Latest-Clinical-Data-from-Multiple-Trials-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","AAPG","BK4168","BK4023","BK4195","EWS","LU1169589451.USD","ORR","PFS","CR","LU1169590202.USD","NB","BK4161","BK4139","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357568","title":"Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357568","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357568?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:02","pubTimestamp":1779397320,"startTime":"0","endTime":"0","summary":"HOUSTON, May  21, 2026  (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299792/0/en/Moleculin-Highlights-Abstract-Accepted-for-Poster-Presentation-at-the-2026-ASCO-Annual-Meeting-Highlighting-Cardiac-Safety-Data-for-Annamycin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.craneco.com","stockEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":0.2039},{"period":"3month","weight":0.2884},{"period":"6month","weight":0.1945},{"period":"1year","weight":0.1694},{"period":"ytd","weight":0.1945}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.1394},{"period":"6month","weight":0.0866},{"period":"1year","weight":0.2051},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.543478,"avgChangeRate":0.020828},{"month":2,"riseRate":0.717391,"avgChangeRate":0.036902},{"month":3,"riseRate":0.565217,"avgChangeRate":0.013749},{"month":4,"riseRate":0.617021,"avgChangeRate":0.003315},{"month":5,"riseRate":0.638298,"avgChangeRate":0.009155},{"month":6,"riseRate":0.595745,"avgChangeRate":0.00936},{"month":7,"riseRate":0.586957,"avgChangeRate":0.004401},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.009516},{"month":9,"riseRate":0.369565,"avgChangeRate":-0.022666},{"month":10,"riseRate":0.586957,"avgChangeRate":0.009396},{"month":11,"riseRate":0.543478,"avgChangeRate":0.025826},{"month":12,"riseRate":0.608696,"avgChangeRate":0.018097}],"exchange":"NYSE","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}